Compound Evidence File
#EC-2026-0589
Halotestin (Fluoxymesterone)
Filed under Oral Tablets. The bureau holds 78 laboratory returns for this compound from 44 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
44 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 25 May 2026 | 25 May 2026 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 10.0 | 10.0 | 10.0 | 13 Jun 2025 | 13 Jun 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 1 | 9.6 | 9.6 | 9.6 | 20 Jun 2025 | 20 Jun 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 9.2 | 8.7 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.9 | 8.0 | 10.0 | 25 May 2026 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.8 | 8.1 | 9.3 | 24 May 2026 | 24 May 2026 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 8.5 | 8.5 | 8.5 | 13 Jun 2025 | 13 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.4 | 7.5 | 9.3 | 24 May 2026 | 24 May 2026 |
| HK PeptidesCASE #VI-2026-0140 | X | 5 | 8.1 | 6.9 | 8.9 | 2 Apr 2025 | 24 May 2026 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 7.9 | 7.9 | 7.9 | 7 May 2025 | 7 May 2025 |
| Mai PeptideCASE #VI-2026-0769 | X | 1 | 7.8 | 7.8 | 7.8 | 7 May 2025 | 7 May 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 7.7 | 7.7 | 7.7 | 11 Jun 2025 | 11 Jun 2025 |
| Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 | X | 1 | 7.6 | 7.6 | 7.6 | 27 Feb 2025 | 27 Feb 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 7.5 | 6.4 | 8.7 | 24 May 2026 | 24 May 2026 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 7.5 | 7.5 | 7.5 | 2 Apr 2025 | 2 Apr 2025 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 7.4 | 7.4 | 7.4 | 16 Mar 2025 | 16 Mar 2025 |
| Welon Peptide SolutionsCASE #VI-2026-0478 | X | 1 | 7.4 | 7.4 | 7.4 | 2 Apr 2025 | 2 Apr 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 7.3 | 6.0 | 8.6 | 2 Jul 2025 | 26 Jan 2026 |
| UtherCASE #VI-2026-0902 | X | 1 | 7.3 | 7.3 | 7.3 | 11 Jun 2025 | 11 Jun 2025 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 7.0 | 7.0 | 7.0 | 2 Jul 2025 | 2 Jul 2025 |
| Orbitrex PeptidesCASE #VI-2026-0812 | X | 1 | 6.8 | 6.8 | 6.8 | 9 Jun 2025 | 9 Jun 2025 |
| Champion PeptideCASE #VI-2026-0909 | X | 1 | 6.6 | 6.6 | 6.6 | 7 May 2025 | 7 May 2025 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 2 | 6.5 | 6.0 | 7.0 | 21 May 2025 | 17 May 2026 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 6.3 | 6.3 | 6.3 | 9 Jun 2025 | 9 Jun 2025 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 5.9 | 5.9 | 5.9 | 9 Jun 2025 | 9 Jun 2025 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 5.7 | 5.7 | 5.7 | 7 May 2025 | 7 May 2025 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 5.7 | 5.7 | 5.7 | 17 Dec 2024 | 17 Dec 2024 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 5.6 | 5.6 | 5.6 | 25 Apr 2025 | 25 Apr 2025 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 5.4 | 5.4 | 5.4 | 21 May 2025 | 21 May 2025 |
| Elite Research USACASE #VI-2026-0267 | X | 4 | 4.8 | 3.6 | 5.8 | 8 Jul 2025 | 17 May 2026 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 4.7 | 4.7 | 4.7 | 25 Apr 2025 | 25 Apr 2025 |
| Modern AminosCASE #VI-2026-0635 | X | 1 | 4.6 | 4.6 | 4.6 | 2 Jul 2025 | 2 Jul 2025 |
| Kerisite Shenzhen InternationalCASE #VI-2026-0315 | X | 1 | 4.6 | 4.6 | 4.6 | 7 May 2025 | 7 May 2025 |
| HybiopeptidesCASE #VI-2026-0305 | X | 1 | 4.3 | 4.3 | 4.3 | 11 Jun 2025 | 11 Jun 2025 |
| Loti LabsCASE #VI-2026-0171 | X | 2 | 4.2 | 4.1 | 4.2 | 3 Jun 2025 | 19 Jan 2026 |
| Peptides For SaleCASE #VI-2026-0614 | X | 1 | 2.9 | 2.9 | 2.9 | 28 Mar 2025 | 28 Mar 2025 |
| Swiss ChemsCASE #VI-2026-0030 | X | 1 | 1.9 | 1.9 | 1.9 | 21 May 2025 | 21 May 2025 |
| Guangzhou Lengiuanhuang CosmeticsCASE #VI-2026-0228 | X | 1 | 1.9 | 1.9 | 1.9 | 27 Feb 2025 | 27 Feb 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 1.8 | 1.8 | 1.8 | 25 Apr 2025 | 25 Apr 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 1.0 | 1.0 | 1.0 | 20 Jun 2025 | 20 Jun 2025 |
| LOOKBiotechCASE #VI-2026-0807 | X | 1 | 0.7 | 0.7 | 0.7 | 21 May 2025 | 21 May 2025 |
| Wuhan Newtop BiotechCASE #VI-2026-0676 | X | 1 | 0.4 | 0.4 | 0.4 | 16 Mar 2025 | 16 Mar 2025 |
| PRIVATECASE #VI-2026-0635 | X | 1 | 0.0 | 0.0 | 0.0 | 25 Apr 2025 | 25 Apr 2025 |
Open any subject to view the batch-level evidence for Halotestin (Fluoxymesterone) alone.